Genetic insights from the PlexusDx Precision Peptide Genetic Test add another dimension to progress monitoring
Many studies indicate that participants can achieve a total weight reduction of around 15-16% of their original body weight by the 68-week mark
You are unsure if your symptoms are related to your GLP-1 medication
In this double-blind, placebo-controlled phase 2, trial, 507 adults with obesity (body mass index 30 kg m 2 or 27 kg m 2 with at least one obesity-associated complication (excluding diabetes) were randomized to nine groups (1:1:1:1:1:1:1:1:1 ratio) to receive treatment for 48 weeks: placebo, bimagrumab (10 mg kg 1 or 30 mg kg 1 intravenously every 12 weeks), semaglutide (1.0 mg or 2.4 mg subcutaneously once a week) and combinations thereof
Additionally, semaglutide slows gastric emptying, which prolongs the sensation of fullness after meals and reduces appetite through effects on appetite centers in the brain
It has been working great